BioPharma Resources

Drug Trial Radar · NCT07208461

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

A Phase Ⅱ, Randomized, Observer-blinded, Placebo-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in Older Adults Aged 60 Years and Older

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Oct 21, 2025

Primary completion

Mar 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.

Conditions

  • Respiratory Syncytial Virus Infection Prevention

Interventions

  • Low dose antigen of LYB005 without A01B adjuvantBiological

    0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.

  • Low dose antigen of LYB005 with A01B adjuvantBiological

    0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.

  • Middle dose antigen of LYB005 without A01B adjuvantBiological

    0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.

  • Middle dose antigen of LYB005 with A01B adjuvantBiological

    0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.

  • High dose antigen of LYB005 without A01B adjuvantBiological

    0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.

  • High dose antigen of LYB005 with A01B adjuvantBiological

    0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.

  • PlaceboBiological

    0.5 mL 0.9% sodium chloride (normal saline) injection per dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The geometric mean titer (GMT) of Neutralizing Antibodies Against RSV A and RSV BTime frame: 30 days after vaccination
  2. Geometric Mean Fold Rise (GMFR) for Neutralizing Antibodies Against RSV A and RSV BTime frame: 30 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Disease Control and Prevention of Dangyang City

    Dangyang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.